Evidence map›Paper›PMID 37989929›Full record

Trial reportBiological trace element research2024

Effects of Zinc Supplementation on Inflammatory Status and Nonalcoholic Steatohepatitis in Overweight or Obese Children: a Randomized Clinical Trial.

Vahidreza Ostadmohammadi, Mohammad Javad Namazi, Mahsa Rezasoltani, Davood Kheirkhah, Mohammad Rajabi, Alireza Sharif, Abbas Taghavi Ardakani, Fariba Raygan, Amelia A Assareh, Mohammad Reza Sharif

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Biological trace element research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vahidreza OstadmohammadiInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. vrom.1993@gmail.com.
Mohammad Javad NamaziInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Mahsa RezasoltaniClinical Research Development Unit, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Davood KheirkhahInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Mohammad RajabiDepartment of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Alireza SharifInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Abbas Taghavi ArdakaniInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Fariba RayganClinical Research Development Unit, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Amelia A AssarehSchool of Psychiatry, University of New South Wales, Sydney, Australia.
Mohammad Reza SharifInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. sharif_m@kaums.ac.ir.

Funding

Research deputy of Kashan University of Medical Sciences, Kashan, Iran grant no. 98214
6 · The paper itself

Abstract

The purpose of the present clinical trial was to determine the impact of zinc supplementation on serum liver enzymes, steatosis severity, lipid profile, and inflammatory status in overweight or obese children with nonalcoholic steatohepatitis (NASH). This randomized controlled trial was conducted by enrolling 60 children with NASH, aged 10-18 years old. The participants were randomly assigned to two groups that received either 30 mg/day of elemental zinc or placebo for 16 weeks. The severity of liver steatosis was evaluated using liver ultrasonography. Fasting blood samples were collected from each patient at the beginning and after 16 weeks of intervention to measure biochemical parameters. Following a 16-week intervention, zinc supplementation compared with placebo significantly decreased serum alanine aminotransferase (ALT) concentrations and high-sensitivity C-reactive protein and considerably enhanced HDL-cholesterol values. However, zinc intake had no considerable impact on aspartate aminotransferase, the severity of liver steatosis, anthropometric parameters, and other lipid indices versus the placebo group. Overall, zinc supplementation showed a promising impact on serum ALT, HDL-cholesterol, and inflammatory status in overweight or obese children suffering from NASH. Zinc supplementation may be a new strategy for the amelioration of NASH in overweight or obese children. This trial has been registered on the Iranian website for registration of clinical trials with the special ID of IRCT20200531047614N1 ( https://www.irct.ir/trial/48543 ).

Indexed as

Dietary SupplementsNon-alcoholic Fatty Liver DiseaseOverweightZincAdolescentAlanine TransaminaseAspartate AminotransferasesChildFemaleHumansInflammationMaleObesityAlanine TransaminaseAspartate AminotransferasesZincC-reactive proteinLipid profileNonalcoholic fatty liver diseaseSteatosis severity

Identifiers

PMID37989929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.